Singapore – A National Health Innovation Ecosystem
Singapore is among the world's most intentionally designed health innovation ecosystems. A city-state of 6 million people, it combines the policy coherence of a small nation with the scientific and commercial weight of a global biomedical hub. Its multi-ethnic Asian population - Chinese, Malay and Indian - makes it uniquely positioned to generate health insights relevant to the world's largest patient populations, filling a critical gap left by research focused predominantly on Western cohorts.
A Government-Led Innovation Mandate
Singapore's health innovation agenda is anchored in the Research, Innovation and Enterprise 2030 (RIE2030) plan, administered by the National Research Foundation (NRF) under the Prime Minister's Office. Under its Human Health and Potential (HHP) domain, RIE2030 focuses on three strategic thrusts: precision health at population scale, global biomedtech and biomanufacturing leadership, and healthy ageing across the life course. The flagship RIE2030 Grand Challenge - Maximising Healthy and Successful Longevity - addresses Singapore's transition to a super-aged society (1 in 4 Singaporeans aged 65+ by 2030) and aims to generate exportable solutions relevant across Asia.
Key government and institutional actors include:
World-Class Research and Academic Medical Institutions
Singapore's universities consistently rank among the world's leading research institutions. NUS ranked 8th and NTU 15th in the 2025 QS World University Rankings. Academic medical centres NUHS and Singapore General Hospital placed 11th and 12th globally in the 2025 Most Reputable AMC Rankings. Singapore has more than 87 researchers in the 2025 Highly Cited Researchers list - a five-fold increase since 2014.
Key academic and research institutions in the ecosystem include:
Precision Medicine, Genomics and Health Data
Singapore's National Precision Medicine (NPM) Programme has built one of the world's largest multi-ethnic Asian genomic databases, with whole genome sequences of over 100,000 Singaporeans. Phase III will expand to 400,000-450,000 participants by 2031. The Biomedical Data Hub provides national infrastructure for health data sharing and analysis. These assets, combined with AI capabilities funded through RIE2030's AI-for-Science initiative, position Singapore as a premier testbed for precision health solutions designed for Asian populations - and scalable globally.
Biotech and MedTech Industry
Under RIE2025, the number of local biomedtech companies in Singapore grew by 60%, from 320 to 493, with a 40% increase in MedTech companies and a doubling of therapeutic biotechs. These companies raised more than US$3.2 billion from local and international investors. The ecosystem includes a diverse range of startups, SMEs and multinationals across diagnostics, digital health, medical devices, RNA therapeutics, and health AI. Notable ecosystem participants include Mirxes (liquid biopsy / cancer early detection), Credo Diagnostics, Roceso Technologies, Microtube Technologies, Sentinan, Sensori Healthcare, Theia Health, and Neurowyzr.
Healthcare Delivery and Social Care
Singapore's healthcare delivery system integrates acute hospital care, polyclinic-based primary care, and a well-developed social and community care sector. The Healthier SG and Age Well SG national programmes drive preventive health and ageing-in-place strategies. The social care and elder care sector - including Lions Befrienders, Moral Home for the Aged Sick, St Luke's Elder Care, Jalan Besar Active Ageing Centre and SG Assist - represents a growing node within the ecosystem as Singapore tackles its demographic transition. Parkway Shenton / IHH Singapore anchors the private healthcare segment.
Innovation Support, Investors and Community Platforms
Singapore's health innovation infrastructure includes: IPI Singapore (innovation marketplace), NUS Enterprise (startup ecosystem), Singapore Venture and Private Capital Association (SVCA), Biotech Connection Singapore, ACE.SG, SGInnovate, Singapore Biodesign, and TUMCREATE (TU Munich research centre in Singapore). The GSMA Southeast Asia presence and Biomedical Data Hub further strengthen connectivity across digital health and health data. MedTech Actuator provides acceleration for medical devices.
Singapore as ASEAN Gateway and International Research Partner
Singapore's regulatory environment - anchored by HSA and aligned with international standards - makes it the natural gateway for health innovation entering ASEAN, Greater China, India, ANZ and Japan. It is the only Southeast Asian country with a complementary funding arrangement for participation in Horizon Europe Pillar II projects. The Singapore-Horizon Europe (SG-HE) Complementary Fund, administered by NRF, allows Singapore-based entities to receive national co-funding when joining EU-led research consortia - creating a direct, government-backed bridge between Singapore's RIE priorities and European collaborative R&D. This mechanism is directly relevant to GHC's cross-border project pipeline.
Global Health Connector will be actively involved in the upcoming Digital Healthcare Summit at GSMA M360 ASEAN on September 9th from 13:40 to 17:15 (Summit Stage – Grand Salon 1). Exploring how advanced connectivity and AI are scaling digital transformation across regional health ecosystems, the session features Gisela García-Álvarez, Executive Director, Global Health Connector APAC, as MC for the session on AI-driven health transformation, alongside GHC Chair Brian O’Connor, who will moderate a high-level panel on healthcare technology strategy and smart hospital investments.
Read more about the Summit here.
The Bridging Horizons Strategic Sessions is a new series of webinars, designed to demystify complex European funding landscapes and connect Singaporean and APAC entities with high-impact, international R&D opportunities.
Webinar Calendar
Session dates, registration and recordings: GHC-APAC Bridging Horizons: Strategic Sessions
Women’s health is increasingly recognised as a key priority for health research and innovation, with important opportunities for stronger international collaboration. This session explores the current landscape of women’s health research in Singapore, alongside relevant Horizon Europe funding opportunities related to women’s health and gender equality. Featuring perspectives from Singaporean research and a European Horizon Europe project, the webinar highlights current challenges, emerging opportunities and lessons from collaborative research initiatives such as the CARDIOCARE project.
Our focus areas mirror Singapore's national priorities and global gaps: healthy ageing and longevity, precision health and genomics, cancer early detection, women's health, and health data governance. We facilitate cross-border partnerships, R&D co-development, investment introductions, and market access pathways between Singapore and the EU, US, Canada and Africa - with Singapore anchoring the APAC end of every connection.
